Corrigendum to "Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [European Neuropsychopharmacology Volume 48, July 2021, Pages 3-31]"

Affiliations

• ¹ Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States. Electronic address: jmccracken@mednet.ucla.edu.
• ² Department of Pediatrics, University of Toronto, Toronto, Canada.
• ³ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Univesitario Gregorio Maranon, and School of Medicine, Universidad Complutense de Madrid, CIBERSAM, Madrid, Spain.
• ⁴ Duke University Medical Center, Durham, North Carolina, United States.
• ⁵ Yale Child Study Center, New Haven, Connecticut, United States.
• ⁶ Institute of Psychiatry, Psychology and Neuroscience, King's College De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom.
• ⁷ Neuroscience Therapeutic Area, Janssen Research & Development, Pennington, New Jersey, United States.
• ⁸ Department of Psychiatry, Columbia University, New York, NY, United States.